SGLT2 Inhibitors vs GLP-1 Agonists: A Cardiologist and an Endocrinologist Weigh In

I thought we would discuss today the whole issue of the new medications for diabetes. We call them new but they're not that new. We're talking about the GLP-1 receptor agonists that have actually been on the market for 17 years. The long-acting ones have been on the market for 15 years. We are also discussing the new SGLT2 inhibitors that came to the market in 2013, so that's 9 years. These drugs are not new anymore. The reason we keep saying "new" is because of the outcomes of recent trials which show that these drugs, which were initially for glucose control, actually have cardiovascular and kidney benefits. We say "new" even though the results are not so new, with outcomes starting to be reported in 2015. If we count, it's already 7 years. Nothing is new in medicine nowadays when we receive double the information every 3 months or so. www.medscape.com/viewarticle/...

[@EternallyGreat]

Wonderful discussion!!

[@divadfeb1959]

Thank you for a good discussion :)

[@davin8r]

Thanks for this talk! Is there any reason to believe that an SGLT2 inhibitor might inhibit atherosclerosis and/or cardiovascular events in a non-diabetic patient with established CVD?

[@divadfeb1959]

Do you see SGLT2 y GLP1 of benefit in early diagnosis of diabetes?

[@omaybishernandez31]

how about patients with electrophysiolohy problems

[@megajatt123]

Raising insulin seems like a stupid outcome to desire. Sglp inhibitors all the way

[@DuffyF56]

Until you get Euglycemic DKA due to the SGLP2 Inhibitor.

[@ricksmith1673]

All questions should compare interventions to intermediate level running if 50 to 60 miles a week. Otherwise the astute physician might conclude that your try to make or keep people sick with a false crowd psychology of laziness :)